TP53 -mutated acute myeloid leukemia: how can we improve outcomes? Available to Purchase

2.

Jaiswal

S

,

Natarajan

P

,

Silver

AJ

, et al.

Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease

.

N Engl J Med

.

2017

;

377

(

2

):

111

-

121

.

3.

Lane

DP

.

How to lose tumor suppression

.

Science

.

2019

;

365

(

6453

):

539

-

540

.

4.

Zhu

J

,

Sammons

MA

,

Donahue

G

, et al.

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

.

Nature

.

2015

;

525

(

7568

):

206

-

211

.

5.

Boettcher

S

,

Miller

PG

,

Sharma

R

, et al.

A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies

.

Science

.

2019

;

365

(

6453

):

599

-

604

.

6.

Chen

S

,

Wang

Q

,

Yu

H

, et al.

Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway

.

Nat Commun

.

2019

;

10

(

1

):

5649

.

7.

Bernard

E

,

Nannya

Y

,

Hasserjian

RP

, et al.

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

.

Nat Med

.

2020

;

26

(

10

):

1549

-

1556

.

8.

Weinberg

OK

,

Siddon

A

,

Madanat

YF

, et al.

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML

.

Blood Adv

.

2022

;

6

(

9

):

2847

-

2853

.

9.

Grob

T

,

Al Hinai

ASA

,

Sanders

MA

, et al.

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

.

Blood

.

2022

;

139

(

15

):

2347

-

2354

.

10.

Aguirre

LE

,

Al Ali

N

,

Jain

AG

, et al.

Characterization of TP53-mutated myelodysplastic syndromes and impact of allelic status and concurrent cytogenetic abnormalities on survival outcomes [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

4034

-

4035

.

11.

Stengel

A

,

Meggendorfer

M

,

Walter

W

, et al.

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS

.

Blood Adv

.

2023

;

7

(

18

):

5540

-

5548

.

12.

Stengel

A

,

Haferlach

T

,

Baer

C

, et al.

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS

.

Blood Adv

.

2023

;

7

(

13

):

2952

-

2956

.

13.

Jaiswal

S

,

Fontanillas

P

,

Flannick

J

, et al.

Age-related clonal hematopoiesis associated with adverse outcomes

.

N Engl J Med

.

2014

;

371

(

26

):

2488

-

2498

.

14.

Weeks

LD

,

Niroula

A

,

Neuberg

D

, et al.

Prediction of risk for myeloid malignancy in clonal hematopoiesis

.

NEJM Evid

.

2023

;

2

(

5

).

15.

Gillis

NK

,

Ball

M

,

Zhang

Q

, et al.

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study

.

Lancet Oncol

.

2017

;

18

(

1

):

112

-

121

.

16.

Takahashi

K

,

Wang

F

,

Kantarjian

H

, et al.

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

.

Lancet Oncol

.

2017

;

18

(

1

):

100

-

111

.

17.

Desai

P

,

Mencia-Trinchant

N

,

Savenkov

O

, et al.

Somatic mutations precede acute myeloid leukemia years before diagnosis

.

Nat Med

.

2018

;

24

(

7

):

1015

-

1023

.

18.

Abelson

S

,

Collord

G

,

Ng

SWK

, et al.

Prediction of acute myeloid leukaemia risk in healthy individuals

.

Nature

.

2018

;

559

(

7714

):

400

-

404

.

19.

Bolton

KL

,

Ptashkin

RN

,

Gao

T

, et al.

Cancer therapy shapes the fitness landscape of clonal hematopoiesis

.

Nat Genet

.

2020

;

52

(

11

):

1219

-

1226

.

20.

Kwan

TT

,

Oza

AM

,

Tinker

AV

, et al.

Preexisting TP53-variant clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer treated with rucaparib

.

JAMA Oncol

.

2021

;

7

(

12

):

1772

-

1781

.

21.

Watson

CJ

,

Papula

AL

,

Poon

GYP

, et al.

The evolutionary dynamics and fitness landscape of clonal hematopoiesis

.

Science

.

2020

;

367

(

6485

):

1449

-

1454

.

22.

Zhao

Z

,

Zuber

J

,

Diaz-Flores

E

, et al.

p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal

.

Genes Dev

.

2010

;

24

(

13

):

1389

-

1402

.

23.

Zhang

J

,

Kong

G

,

Rajagopalan

A

, et al.

p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia

.

Blood

.

2017

;

129

(

3

):

358

-

370

.

24.

Wong

TN

,

Ramsingh

G

,

Young

AL

, et al.

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

.

Nature

.

2015

;

518

(

7540

):

552

-

555

.

25.

Kennedy

AL

,

Myers

KC

,

Bowman

J

, et al.

Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome

.

Nat Commun

.

2021

;

12

(

1

):

1334

.

26.

Xia

J

,

Miller

CA

,

Baty

J

, et al.

Somatic mutations and clonal hematopoiesis in congenital neutropenia

.

Blood

.

2018

;

131

(

4

):

408

-

416

.

27.

Sallman

DA

,

McLemore

AF

,

Aldrich

AL

, et al.

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

.

Blood

.

2020

;

136

(

24

):

2812

-

2823

.

28.

Williams

P

,

Basu

S

,

Garcia-Manero

G

, et al.

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

.

Cancer

.

2019

;

125

(

9

):

1470

-

1481

.

https://doi.org/10.1101/2023.09.04.23295042

29.

Jambhekar

A

,

Ackerman

EE

,

Alpay

BA

,

Lahav

G

,

Lovitch

SB

.

Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression

.

medRxiv

.

Preprint posted online 5 September 2023

.

30.

Morganti

S

,

Gibson

CJ

,

Jin

Q

, et al.

Prevalence, dynamics, and prognostic role of clonal hematopoiesis of indeterminate potential in patients with breast cancer

.

J Clin Oncol

.

2024

:

JCO2301071

.

31.

Khoury

JD

,

Solary

E

,

Abla

O

, et al.

The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1703

-

1719

.

32.

Arber

DA

,

Orazi

A

,

Hasserjian

RP

, et al.

International Consensus Classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data

.

Blood

.

2022

;

140

(

11

):

1200

-

1228

.

33.

Bernard

E

,

Nannya

Y

,

Hasserjian

RP

, et al.

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

.

Nat Med

.

2020

;

26

(

10

):

1549

-

1556

.

34.

Bahaj

W

,

Kewan

T

,

Gurnari

C

, et al.

Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia

.

J Hematol Oncol

.

2023

;

16

(

1

):

91

.

35.

Sallman

DA

,

Komrokji

R

,

Vaupel

C

, et al.

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

.

Leukemia

.

2016

;

30

(

3

):

666

-

673

.

36.

Daver

NG

,

Maiti

A

,

Kadia

TM

, et al.

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions

.

Cancer Discov

.

2022

;

12

(

11

):

2516

-

2529

.

37.

DiGennaro

J

,

Sallman

DA

.

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: current guidelines, therapies, and future considerations

.

Acta Haematol

.

2024

;

147

(

2

):

175

-

185

.

38.

Daver

NG

,

Iqbal

S

,

Renard

C

, et al.

Treatment outcomes for newly diagnosed, treatment-naive TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis

.

J Hematol Oncol

.

2023

;

16

(

1

):

19

.

39.

Welch

JS

,

Petti

AA

,

Miller

CA

, et al.

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes

.

N Engl J Med

.

2016

;

375

(

21

):

2023

-

2036

.

40.

DiNardo

CD

,

Jonas

BA

,

Pullarkat

V

, et al.

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

.

N Engl J Med

.

2020

;

383

(

7

):

617

-

629

.

41.

Shimony

S

,

Garcia

JS

,

Keating

J

, et al.

Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients

.

Leukemia

.

2024

;

38

(

7

):

1494

-

1500

.

42.

Gruszczynska

A

,

Maiti

A

,

Miller

CA

, et al.

Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes

.

Haematologica

.

2024

;

109

(

8

):

2653

-

2659

.

43.

Short

NJ

,

Montalban-Bravo

G

,

Hwang

H

, et al.

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

.

Blood Adv

.

2020

;

4

(

22

):

5681

-

5689

.

44.

Lemoli

RM

,

Montesinos

P

,

Jain

A

.

Real-world experience with CPX-351 in high-risk acute myeloid leukemia

.

Crit Rev Oncol Hematol

.

2023

;

185

:

103984

.

45.

Stengel

A

,

Haferlach

T

,

Baer

C

, et al.

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS

.

Blood Adv

.

2023

;

7

(

13

):

2952

-

2956

.

46.

Sallman

DA

,

DeZern

AE

,

Garcia-Manero

G

, et al.

Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes

.

J Clin Oncol

.

2021

;

39

(

14

):

1584

-

1594

.

47.

Cluzeau

T

,

Sebert

M

,

Rahme

R

, et al.

Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myelodysplasies (GFM)

.

J Clin Oncol

.

2021

;

39

(

14

):

1575

-

1583

.

48.

Daver

NG

,

Vyas

P

,

Kambhampati

S

, et al.

Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results

.

J Clin Oncol

.

2023

;

41

(

31

):

4893

-

4904

.

49.

Mishra

A

,

Tamari

R

,

DeZern

AE

, et al.

Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes

.

J Clin Oncol

.

2022

;

40

(

34

):

3985

-

3993

.

50.

Garcia-Manero

G

,

Goldberg

AD

,

Winer

ES

, et al.

Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study

.

Lancet Haematol

.

2023

;

10

(

4

):

e272

-

e283

.

51.

Sallman

DA

,

Komrokji

RS

,

DeZern

AE

, et al.

Long term follow-up and combined phase 2 results of eprenetapopt (APR-246) and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML) [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

246

.

52.

Aprea therapeutics announces results of primary endpoint from phase 3 trial of eprenetapopt in TP53 mutant myelodysplastic syndromes (MDS). News Release. Aprea Therapeutics; December 28, 2020

. Accessed 24 September 2024. https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-announces-results-primary-endpoint-phase-3.

53.

Kruer

TL

,

Quintana

A

,

Ferrall-Fairbanks

M

, et al.

XPO1 overexpression is a mechanism of resistance to eprenetapopt and 5-azacitidine therapy that can be therapeutically exploited for the treatment of TP53 mutated myeloid malignancies [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

99

-

100

.

54.

Carter

BZ

,

Mak

PY

,

Ke

B

, et al.

Selective targeting of TP53-Y220C mutant AML by PC14586 results in TP53 wild-type conformation and synergistical apoptosis induction by concomitant inhibition of XPO-1, MDM2, or BCL-2 [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

2261

.

55.

Sallman

DA

,

Al Malki

MM

,

Asch

AS

, et al.

Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study

.

J Clin Oncol

.

2023

;

41

(

15

):

2815

-

2826

.

56.

Gilead

.

Magrolimab trials summary

. Accessed 24 September 2024. https://www.gilead.com/-/media/files/pdfs/other/magrolimab-trials-summary.pdf.

57.

Zeidan

AM

,

Xiao

Z

,

Sanz

G

, et al. Primary results of the phase III stimulus-MDS2 study of sabatolimab + azacitidine vs placebo + azacitidine as frontline therapy for patients with higher-risk MDS or CMML-2. Abstract presented at: 29th European Hematology Association Congress.

June 13-16, 2024

. Madrid, Spain.

58.

Lindsley

RC

,

Saber

W

,

Mar

BG

, et al.

Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation

.

N Engl J Med

.

2017

;

376

(

6

):

536

-

547

.

59.

Versluis

J

,

Saber

W

,

Tsai

HK

, et al.

Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 study

.

J Clin Oncol

.

2023

;

41

(

28

):

4497

-

4510

.

60.

Loke

J

,

Labopin

M

,

Craddock

C

, et al.

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia

.

Cancer

.

2022

;

128

(

15

):

2922

-

2931

.

61.

Yoshizato

T

,

Nannya

Y

,

Atsuta

Y

, et al.

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation

.

Blood

.

2017

;

129

(

17

):

2347

-

2358

.

62.

Nawas

MT

,

Kosuri

S

.

Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML

.

Blood Adv

.

2024

;

8

(

3

):

553

-

561

.

63.

Badar

T

,

Atallah

E

,

Shallis

RM

, et al.

Outcomes of TP53-mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival

.

Am J Hematol

.

2022

;

97

(

7

):

E232

-

E235

.

64.

Badar

T

,

Atallah

E

,

Shallis

R

, et al.

Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

.

Leukemia

.

2023

;

37

(

4

):

799

-

806

.

65.

Versluis

J

,

Lindsley

RC

.

Transplant for TP53-mutated MDS and AML: because we can or because we should?

.

Hematology Am Soc Hematol Educ Program

.

2022

;

2022

(

1

):

522

-

527

.

66.

Hunter

AM

,

Komrokji

RS

,

Yun

S

, et al.

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

.

Blood Adv

.

2021

;

5

(

4

):

1017

-

1028

.

67.

Yun

S

,

Geyer

SM

,

Komrokji

RS

, et al.

Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)

.

Leukemia

.

2021

;

35

(

4

):

1145

-

1155

.